相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rheos An Implantable Carotid Sinus Stimulation Device for the Nonpharmacologic Treatment of Resistant Hypertension
Maria M. Ng et al.
CARDIOLOGY IN REVIEW (2011)
Device-Based Antihypertensive Therapy Therapeutic Modulation of the Autonomic Nervous System
Henry Krum et al.
CIRCULATION (2011)
Role of renalase in the regulation of blood pressure and the renal dopamine system
Gary V. Desir
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2011)
Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Fixed-Dose Combination in Hypertension
Emma D. Deeks
DRUGS (2011)
Novel procedure- and device-based strategies in the management of systemic hypertension
Henry Krum et al.
EUROPEAN HEART JOURNAL (2011)
Metabolic Actions Could Confound Advantageous Effects of Combined Angiotensin II Receptor and Neprilysin Inhibition
Andreas L. Birkenfeld et al.
HYPERTENSION (2011)
Treatment Considerations With Aldosterone Receptor Antagonists
Domenic A. Sica et al.
JOURNAL OF CLINICAL HYPERTENSION (2011)
Translational medicine: the antihypertensive effect of renal denervation
Gerald F. DiBona et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2010)
Triple Therapy With Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide in Adult Patients With Hypertension: The TRINITY Multicenter, Randomized, Double-Blind, 12-Week, Parallel-Group Study
Suzanne Oparil et al.
CLINICAL THERAPEUTICS (2010)
New Therapeutic Approaches to Resistant Hypertension
Markus P. Schlaich et al.
CURRENT HYPERTENSION REPORTS (2010)
Vascular Relaxation, Antihypertensive Effect, and Cardioprotection of a Novel Peptide Agonist of the Mas Receptor
Silvia Quintao Savergnini et al.
HYPERTENSION (2010)
Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor κB
Franziska Rompe et al.
HYPERTENSION (2010)
DORADO: Opportunity Postponed Lessons From Studies of Endothelin Receptor Antagonists in Treatment-Resistant Hypertension
David J. Webb
HYPERTENSION (2010)
Divergent Results Using Clinic and Ambulatory Blood Pressures Report of a Darusentan-Resistant Hypertension Trial
George L. Bakris et al.
HYPERTENSION (2010)
Aldosterone Synthase Inhibition With LCI699 A Proof-of-Concept Study in Patients With Primary Aldosteronism
Laurence Amar et al.
HYPERTENSION (2010)
Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage
Heiko Funke-Kaiser et al.
HYPERTENSION RESEARCH (2010)
Possible roles of human (pro)renin receptor suggested by recent clinical and experimental findings
Atsuhiro Ichihara et al.
HYPERTENSION RESEARCH (2010)
Sympathetic nerve activity is decreased during device-guided slow breathing
Bruna Oneda et al.
HYPERTENSION RESEARCH (2010)
A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
Jerome Fagart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Board of Directors and Membership Benefits
Journal of Clinical Hypertension (2010)
Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial
D. A. Duprez et al.
JOURNAL OF HUMAN HYPERTENSION (2010)
Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report
K. Gaddam et al.
JOURNAL OF HUMAN HYPERTENSION (2010)
FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice
Aviva Gamliel-Lazarovich et al.
JOURNAL OF HYPERTENSION (2010)
Anti-Inflammatory Effects of the Activation of the Angiotensin-(1-7) Receptor, Mas, in Experimental Models of Arthritis
Katia Daniela da Silveira et al.
JOURNAL OF IMMUNOLOGY (2010)
Stereochemical Requirements for the Mineralocorticoid Receptor Antagonist Activity of Dihydropyridines
Graciela B. Arhancet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Novel Baroreflex Activation Therapy in Resistant Hypertension Results of a European Multi-Center Feasibility Study
Ingrid J. M. Scheffers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Adapter proteins and promoter regulation of the angiotensin AT2 receptor - implications for cardiac pathophysiology
Heiko Funke-Kaiser et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2010)
Renal sympathetic denervation: the jury is still out
Michael Doumas et al.
LANCET (2010)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
Murray D. Esler et al.
LANCET (2010)
Novel therapeutic targets for hypertension
Ludovit Paulis et al.
NATURE REVIEWS CARDIOLOGY (2010)
Requirement of Prorenin Receptor and Vacuolar H+-ATPase-Mediated Acidification for Wnt Signaling
Cristina-Maria Cruciat et al.
SCIENCE (2010)
A Randomized Controlled Trial on Effects of the Transcendental Meditation Program on Blood Pressure, Psychological Distress, and Coping in Young Adults
Sanford I. Nidich et al.
AMERICAN JOURNAL OF HYPERTENSION (2009)
Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats
Bing S. Huang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2009)
Prorenin has high affinity multiple binding sites for (pro)renin receptor
A. H. M. Nurun Nabi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2009)
Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide
Roland E. Schmieder et al.
CIRCULATION (2009)
Inhibition of Zinc Metallopeptidases in Cardiovascular Disease - From Unity to Trinity, or Duality?
Vincent Dive et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
(Pro)renin Receptor-Mediated Signal Transduction and Tissue Renin-Angiotensin System Contribute to Diabetes-Induced Retinal Inflammation
Shingo Satofuka et al.
DIABETES (2009)
Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R
Tsuyoshi Isaka et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Possible contribution of the non-proteolytic activation of prorenin to the development of insulin resistance in fructose-fed rats
Yukiko Nagai et al.
EXPERIMENTAL PHYSIOLOGY (2009)
Chronic Treatment With Losartan Results in Sufficient Serum Levels of the Metabolite EXP3179 for PPARγ Activation
Kai Kappert et al.
HYPERTENSION (2009)
Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide A Randomized Clinical Trial
David A. Calhoun et al.
HYPERTENSION (2009)
Triple Fixed-Dose Combination Therapy Back to the Past
Henry R. Black
HYPERTENSION (2009)
Renal Denervation as a Therapeutic Approach for Hypertension Novel Implications for an Old Concept
Markus P. Schlaich et al.
HYPERTENSION (2009)
Next generation multifunctional angiotensin receptor blockers
Theodore W. Kurtz et al.
HYPERTENSION RESEARCH (2009)
Immediate Effect of Slow Pace Bhastrika Pranayama on Blood Pressure and Heart Rate
Tapas Pramanik et al.
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE (2009)
ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy
Ulrich Kintscher
JOURNAL OF HYPERTENSION (2009)
Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
Uzma F. Mehdi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
William B. Lea et al.
KIDNEY INTERNATIONAL (2009)
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
Michael A. Weber et al.
LANCET (2009)
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
Henry Krum et al.
LANCET (2009)
Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet
Dinko Susic et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
N. S. Kirkby et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Angiotensin II Type 2 Receptor Stimulation A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?
Elena Kaschina et al.
CIRCULATION (2008)
Catecholamines regulate the activity, secretion, and synthesis of renalase
Guoyong Li et al.
CIRCULATION (2008)
Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure? (Reprinted from Current Cardiovascular Risk Reports, vol 1, number 3)
Domenic A. Sica
CURRENT HYPERTENSION REPORTS (2008)
Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
Paul Mulder et al.
EUROPEAN HEART JOURNAL (2008)
Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R
Osamu Akizuki et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism
Asterios Karagiannis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Rheos (R) Baroreflex Hypertension Therapy (TM) System to treat resistant hypertension
Ingrid J. M. Scheffers et al.
EXPERT REVIEW OF MEDICAL DEVICES (2008)
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity
Jessica D. Dietz et al.
HYPERTENSION (2008)
Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes
Marco F. Dias-Peixoto et al.
HYPERTENSION (2008)
Endothelin receptor antagonism - What does the future hold?
Domenic A. Sica
HYPERTENSION (2008)
Prorenin engages the (pro) renin receptor like renin and both ligand activities are unopposed by aliskiren
Jan H. Schefe et al.
JOURNAL OF HYPERTENSION (2008)
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial
Karl Andersen et al.
JOURNAL OF HYPERTENSION (2008)
Renin-angiotensin system revisited
F. Fyhrquist et al.
JOURNAL OF INTERNAL MEDICINE (2008)
PLZF and the (pro)renin receptor
Jan H. Schefe et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
Chronotherapy beyond blood pressure reduction?
Fedor Simko et al.
JOURNAL OF PINEAL RESEARCH (2008)
The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling
Sandra Feldt et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Renin report - Official publication of the members of the Renin Academy
A. H. Jan Danser et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2008)
Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension
Rainer Dietz et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2008)
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure:: a double-blind, randomised, placebo-controlled phase IIa study
Alain C. Tissot et al.
LANCET (2008)
The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets
Rodrigo Araujo Fraga-Silva et al.
MOLECULAR MEDICINE (2008)
Telmisartan, ramipril, or both in patients at high risk for vascular events
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Beyond the classic angiotensin-receptor-blocker profile
Theodore W. Kurtz
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Selective and mixed endothelin receptor antagonism in cardiovascular disease
Neeraj Dhaun et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population
Qi Zhao et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
AT1 receptor antisense therapy transiently lowers blood pressure in Ren-2 transgenic rats
Ivana Vaneckova et al.
VASCULAR PHARMACOLOGY (2007)
2007 Guidelines for the management of arterial hypertension - The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)
Giuseppe Mancia et al.
EUROPEAN HEART JOURNAL (2007)
Aliskiren, the first renin inhibitor for treating hypertension: Reactive renin secretion may limit its effectiveness
Jean E. Sealey et al.
AMERICAN JOURNAL OF HYPERTENSION (2007)
Knocking down the diencephalic thyrotropin-releasing hormone precursor gene normalizes obesity-induced hypertension in the rat
Maria S. Landa et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Effect of spironolactone on blood pressure in subjects with resistant hypertension
Neil Chapman et al.
HYPERTENSION (2007)
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension
Thomas Philipp et al.
CLINICAL THERAPEUTICS (2007)
Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor
Hongwei Li et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2007)
Incident diabetes in clinical trials of anti hypertensive drugs: a network meta-analysis
William J. Elliott et al.
LANCET (2007)
A vaccine for hypertension based on virus-like particles:: preclinical efficacy and phase I safety and immunogenicity
Patrice M. Ambuehl et al.
JOURNAL OF HYPERTENSION (2007)
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults
James L. Pool et al.
CLINICAL THERAPEUTICS (2007)
Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization
Shingo Satofuka et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Low-dose spironolactone in the management of resistant hypertension: a surveillance study
Deirdre A. Lane et al.
JOURNAL OF HYPERTENSION (2007)
A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein
Jan H. Schefe et al.
CIRCULATION RESEARCH (2006)
An implantable carotid sinus stimulator for drug-resistant hypertension: Surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial
Karl A. Illig et al.
JOURNAL OF VASCULAR SURGERY (2006)
New drugs for hypertension: What do, they offer?
Alan H. Gradman et al.
CURRENT HYPERTENSION REPORTS (2006)
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
Murray Epstein et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice
Atsuhiro Ichihara et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension
A Ichihara et al.
HYPERTENSION (2006)
Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang-(1-7)
LD Lara et al.
BIOCHEMICAL JOURNAL (2006)
Familial hyperkalemic hypertension
Juliette Hadchouel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Renin increases mesangial cell transforming growth factor-beta 1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms
Y Huang et al.
KIDNEY INTERNATIONAL (2006)
Baroreflex activation for the treatment of hypertension: principles and practice
Domenic A. Sica et al.
EXPERT REVIEW OF MEDICAL DEVICES (2006)
Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells
K Imagawa et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2006)
Effects of eplerenone versus losartan in patients with low-renin hypertension
MH Weinberger et al.
AMERICAN HEART JOURNAL (2005)
Aldosterone synthase inhibitor ameliorates angiotensin II - Induced organ damage
A Fiebeler et al.
CIRCULATION (2005)
Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure
JC Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Recent insights into the interactions between the baroreflex and the kidneys in hypertension
TE Lohmeier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2005)
Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis
D Sica
HEART FAILURE REVIEWS (2005)
Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats
MJ Huentelman et al.
EXPERIMENTAL PHYSIOLOGY (2005)
Prolonged hypotensive effect of human tissue kallikrein gene delivery and recombinant enzyme administration in spontaneous hypertension rats
HC Sun et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2004)
Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial
OB Kostis et al.
AMERICAN JOURNAL OF HYPERTENSION (2004)
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the handle'' region for nonproteolytic activation of prorenin
A Ichihara et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects
MJ Brown et al.
CLINICAL SCIENCE (2004)
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
S Julius et al.
LANCET (2004)
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy - The 4E-left ventricular hypertrophy study
B Pitt et al.
CIRCULATION (2003)
Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats
G Bledsoe et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas
RAS Santos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Vasopeptidase inhibition - A double-edged sword?
DJ Campbell
HYPERTENSION (2003)
Aldosterone-induced cardiac damage: Focus on blood pressure independent effects
BMW Schmidt et al.
AMERICAN JOURNAL OF HYPERTENSION (2003)
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren
A Stanton et al.
HYPERTENSION (2003)
Efficacy of low-dose spironolactone in subjects with resistant hypertension
MK Nishizaka et al.
AMERICAN JOURNAL OF HYPERTENSION (2003)
Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)
M Packer et al.
CIRCULATION (2002)
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
MH Weinberger et al.
AMERICAN JOURNAL OF HYPERTENSION (2002)
Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin
G Nguyen et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Rationale for fixed-dose combinations in the treatment of hypertension - The cycle repeats
DA Sica
DRUGS (2002)
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100) - Comparison with enalapril
J Nussberger et al.
HYPERTENSION (2002)
Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase
AL Albiston et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Renin antisense injected intraventricularly decreases blood pressure in spontaneously hypertensive rats
T Kubo et al.
BRAIN RESEARCH BULLETIN (2001)
The sympathetic nervous system and long-term blood pressure regulation
TE Lohmeier
AMERICAN JOURNAL OF HYPERTENSION (2001)
Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition
LV d'Uscio et al.
HYPERTENSION (2001)
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
M Donoghue et al.
CIRCULATION RESEARCH (2000)
Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats
HD Intengan et al.
HYPERTENSION (2000)
Angiotensin II antagonists for hypertension: Are there differences in efficacy?
PR Conlin et al.
AMERICAN JOURNAL OF HYPERTENSION (2000)
分享论文
